Kaleido Biosciences, Inc. Common Stock
KLDO
KLDO was delisted on the 14th of April, 2022.
56 hedge funds and large institutions have $320M invested in Kaleido Biosciences, Inc. Common Stock in 2020 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 13 closing their positions.
50% more capital invested
Capital invested by funds: $213M → $320M (+$107M)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 16
7% less funds holding
Funds holding: 60 → 56 (-4)
31% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 13
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.02M |
| 2 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
+$597K |
| 3 |
Charles Schwab
San Francisco,
California
|
+$382K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$234K |
| 5 |
First Trust Advisors
Wheaton,
Illinois
|
+$198K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MIM
Monashee Investment Management
Boston,
Massachusetts
|
-$1.11M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$558K |
| 3 |
HI
HBK Investments
Dallas,
Texas
|
-$480K |
| 4 |
Citigroup
New York
|
-$409K |
| 5 |
LCM
Laurion Capital Management
New York
|
-$382K |
KLDO Hedge Fund Activity: Q3 2020 in Review
56 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in Kaleido Biosciences, Inc. Common Stock (KLDO) for Q3 2020, worth a combined $320M — up 50% from $213M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of KLDO and 9 opened new positions — a net loss of 4 holders — while 16 trimmed existing stakes and 16 added.
The largest buyer was Fidelity Investments, adding an estimated $3.02M. The largest seller was Monashee Investment Management, exiting entirely with an estimated $1.11M sold.
- 56 institutional investors held Kaleido Biosciences, Inc. Common Stock (KLDO) as of Q3 2020, down from 60 in Q2 2020.
- Funds reported $320M of Kaleido Biosciences, Inc. Common Stock stock for Q3 2020, up 50% quarter-over-quarter.
- 9 funds opened new Kaleido Biosciences, Inc. Common Stock positions in Q3 2020 and 13 closed out, a net change of -4 holders.
- The largest Kaleido Biosciences, Inc. Common Stock buyer in Q3 2020 was Fidelity Investments, an estimated $3.02M added.
- The largest Kaleido Biosciences, Inc. Common Stock seller in Q3 2020 was Monashee Investment Management, an estimated $1.11M sold.
Based on aggregated 13F filings for Q3 2020.